Risk of serious adverse reactions in patients with hereditary fructose intolerance due to sorbitol excipient.
- TRADE NAME: Praxbind (Boehringer Ingelheim)
- INDICATIONS: Reversal of the anticoagulant effects of dabigatran in patients requiring emergency or urgent surgery or with life-threatening or uncontrolled bleeding
- CLASS: Monoclonal antibody, Reversal agent for dabigatran
- HALF-LIFE: 10 hours
- FDA APPROVAL DATE: 10/16/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No data available
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
